Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, presented research findings at the American Academy of Dermatology Meeting on March 30, 2026, highlighting safety and efficacy data for its investigational neurotoxin trenibotulinumtoxinE (TrenibotE) and patient behaviors related to GLP-1 agonist treatments.

The company presented data from an 18-week, open-label Phase 3 study evaluating repeat TrenibotE treatments for glabellar lines. The study showed TrenibotE was well-tolerated over three sequential treatments with a consistent safety profile and no neutralizing antibody development. The investigational neurotoxin demonstrated rapid onset of results as early as eight hours after administration with a shorter duration of effect of 2-3 weeks compared to existing treatments.

TrenibotE is described as a first-in-class botulinum neurotoxin serotype E. If approved, it would be the first neurotoxin of its kind available to patients, according to the company's statement.

Allergan Aesthetics also presented survey data on GLP-1 agonist patients seeking aesthetic treatments. The research indicated that 52% of GLP-1-treated patients expressed concern about their facial appearance during treatment. Healthcare professionals reported that 32% of GLP-1-treated patients are new to their aesthetic practices.

The survey identified cost as the primary barrier preventing these patients from receiving aesthetic treatments at 82%, followed by fear of unnatural results at 58%. Patients receiving GLP-1 treatment were reported to be predominantly white (64%), female (70%), and between 30-49 years of age (56%).

"Our data presented at AAD advance knowledge of our market-leading and emerging portfolio to deliver safe and effective treatments that address patients' aesthetic concerns," said John Maltman, Ph.D., vice president of global aesthetics medical affairs at Allergan Aesthetics.

The company presented four posters in total at the conference, including additional research on topical cosmetic hydrating serums and patient satisfaction with VYC-12L treatments for neck appearance.